These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38272561)

  • 1. Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders.
    Huffman BM; Singh H; Ali LR; Horick N; Wang SJ; Hoffman MT; Metayer KA; Murray S; Bird A; Abrams TA; Biller LH; Chan JA; Meyerhardt JA; McCleary NJ; Goessling W; Patel AK; Wisch JS; Yurgelun MB; Mouw K; Reardon B; Van Allen EM; Zerillo JA; Clark JW; Parikh A; Mayer RJ; Schlechter B; Ng K; Kumar S; Del Vecchio Fitz C; Kuperwasser C; Hanna GJ; Coveler AL; Rubinson DA; Welsh EL; Pfaff K; Rodig S; Dougan SK; Cleary JM
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38272561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.
    Ott PA; Piha-Paul SA; Munster P; Pishvaian MJ; van Brummelen EMJ; Cohen RB; Gomez-Roca C; Ejadi S; Stein M; Chan E; Simonelli M; Morosky A; Saraf S; Emancipator K; Koshiji M; Bennouna J
    Ann Oncol; 2017 May; 28(5):1036-1041. PubMed ID: 28453692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study.
    Marabelle A; Cassier PA; Fakih M; Kao S; Nielsen D; Italiano A; Guren TK; van Dongen MGJ; Spencer K; Bariani GM; Ascierto PA; Santoro A; Shah M; Asselah J; Iqbal S; Takahashi S; Piha-Paul SA; Ott PA; Chatterjee A; Jin F; Norwood K; Delord JP
    Lancet Gastroenterol Hepatol; 2022 May; 7(5):446-454. PubMed ID: 35114169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HPV circulating tumor DNA to monitor the efficacy of anti-PD-1 therapy in metastatic squamous cell carcinoma of the anal canal: A case report.
    Cabel L; Bidard FC; Servois V; Cacheux W; Mariani P; Romano E; Minsat M; Bieche I; Farkhondeh F; Jeannot E; Buecher B
    Int J Cancer; 2017 Oct; 141(8):1667-1670. PubMed ID: 28670746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial.
    Hughes BGM; Munoz-Couselo E; Mortier L; Bratland Å; Gutzmer R; Roshdy O; González Mendoza R; Schachter J; Arance A; Grange F; Meyer N; Joshi A; Billan S; Zhang P; Gumuscu B; Swaby RF; Grob JJ
    Ann Oncol; 2021 Oct; 32(10):1276-1285. PubMed ID: 34293460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of Liquid Biopsy for Diagnosis and Surveillance of Human Papillomavirus-Associated Oropharyngeal Cancer.
    Ferrandino RM; Chen S; Kappauf C; Barlow J; Gold BS; Berger MH; Westra WH; Teng MS; Khan MN; Posner MR; Misiukiewicz KJ; Bakst RL; Sindhu KK; Genden EM; Chai RL; Roof SA
    JAMA Otolaryngol Head Neck Surg; 2023 Nov; 149(11):971-977. PubMed ID: 37422913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
    Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ
    Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma.
    Jackovich A; Gitlitz BJ; Tiu-Lim JWW; Duddalwar V; King KG; El-Khoueiry AB; Thomas JS; Tsao-Wei D; Quinn DI; Gill PS; Nieva JJ
    Oncotarget; 2024 Jul; 15():444-458. PubMed ID: 38985143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas.
    Maubec E; Boubaya M; Petrow P; Beylot-Barry M; Basset-Seguin N; Deschamps L; Grob JJ; Dréno B; Scheer-Senyarich I; Bloch-Queyrat C; Leccia MT; Stefan A; Saiag P; Grange F; Meyer N; de Quatrebarbes J; Dinulescu M; Legoupil D; Machet L; Dereure O; Zehou O; Montaudié H; Wierzbicka-Hainaut E; Le Corre Y; Mansard S; Guégan S; Arnault JP; Dalac S; Aubin F; Alloux C; Lopez I; Cherbal S; Tibi A; Lévy V;
    J Clin Oncol; 2020 Sep; 38(26):3051-3061. PubMed ID: 32730186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.
    Loi S; Giobbie-Hurder A; Gombos A; Bachelot T; Hui R; Curigliano G; Campone M; Biganzoli L; Bonnefoi H; Jerusalem G; Bartsch R; Rabaglio-Poretti M; Kammler R; Maibach R; Smyth MJ; Di Leo A; Colleoni M; Viale G; Regan MM; André F;
    Lancet Oncol; 2019 Mar; 20(3):371-382. PubMed ID: 30765258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy in Locally Advanced Anal Canal Squamous Cell Carcinoma Patients: Antitumor Efficacy, Safety and Biomarker Analysis.
    Xiao W; Yuan Y; Wang S; Liao Z; Cai P; Chen B; Zhang R; Wang F; Zeng Z; Gao Y
    Front Immunol; 2021; 12():798451. PubMed ID: 35095878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
    Chow LQM; Haddad R; Gupta S; Mahipal A; Mehra R; Tahara M; Berger R; Eder JP; Burtness B; Lee SH; Keam B; Kang H; Muro K; Weiss J; Geva R; Lin CC; Chung HC; Meister A; Dolled-Filhart M; Pathiraja K; Cheng JD; Seiwert TY
    J Clin Oncol; 2016 Nov; 34(32):3838-3845. PubMed ID: 27646946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
    Ott PA; Bang YJ; Piha-Paul SA; Razak ARA; Bennouna J; Soria JC; Rugo HS; Cohen RB; O'Neil BH; Mehnert JM; Lopez J; Doi T; van Brummelen EMJ; Cristescu R; Yang P; Emancipator K; Stein K; Ayers M; Joe AK; Lunceford JK
    J Clin Oncol; 2019 Feb; 37(4):318-327. PubMed ID: 30557521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumor tissue modified viral (TTMV)-HPV DNA in Recurrent, metastatic HPV-driven oropharyngeal cancer.
    Hanna GJ; Jabalee J; Lukens JN; Sun L; Rettig EM; Ferrandino R; Posner MR; Misiukiewicz KJ; Routman DM; Van Abel KM; Del Vecchio Fitz C; Roof SA
    Oral Oncol; 2024 Nov; 158():107002. PubMed ID: 39159525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study.
    Lonardi S; Prete AA; Morano F; Messina M; Formica V; Corsi DC; Orciuolo C; Frassineti GL; Zampino MG; Casagrande M; Masi G; Ronzoni M; Scartozzi M; Buonadonna A; Mosconi S; Ratti M; Sartore-Bianchi A; Tamburini E; Prisciandaro M; Bergamo F; Spada M; Corallo S; Vettore V; Loupakis F; Fassan M; Del Bianco P; Zagonel V; Pietrantonio F
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34815354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202).
    Rao S; Anandappa G; Capdevila J; Dahan L; Evesque L; Kim S; Saunders MP; Gilbert DC; Jensen LH; Samalin E; Spindler KL; Tamberi S; Demols A; Guren MG; Arnold D; Fakih M; Kayyal T; Cornfeld M; Tian C; Catlett M; Smith M; Spano JP
    ESMO Open; 2022 Aug; 7(4):100529. PubMed ID: 35816951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma.
    Feun LG; Li YY; Wu C; Wangpaichitr M; Jones PD; Richman SP; Madrazo B; Kwon D; Garcia-Buitrago M; Martin P; Hosein PJ; Savaraj N
    Cancer; 2019 Oct; 125(20):3603-3614. PubMed ID: 31251403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy.
    Yanik EL; Kaunitz GJ; Cottrell TR; Succaria F; McMiller TL; Ascierto ML; Esandrio J; Xu H; Ogurtsova A; Cornish T; Lipson EJ; Topalian SL; Engels EA; Taube JM
    JAMA Oncol; 2017 Jul; 3(7):974-978. PubMed ID: 28334399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Pretreatment Circulating Tumor Tissue-Modified Viral HPV DNA With Clinicopathologic Factors in HPV-Positive Oropharyngeal Cancer.
    Rettig EM; Wang AA; Tran NA; Carey E; Dey T; Schoenfeld JD; Sehgal K; Guenette JP; Margalit DN; Sethi R; Uppaluri R; Tishler RB; Annino DJ; Goguen LA; Jo VY; Haddad RI; Hanna GJ
    JAMA Otolaryngol Head Neck Surg; 2022 Dec; 148(12):1120-1130. PubMed ID: 36301568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study.
    Taylor MH; Betts CB; Maloney L; Nadler E; Algazi A; Guarino MJ; Nemunaitis J; Jimeno A; Patel P; Munugalavadla V; Tao L; Adkins D; Goldschmidt JH; Cohen EEW; Coussens LM
    Clin Cancer Res; 2022 Mar; 28(5):903-914. PubMed ID: 34862248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.